NCT00090077已完成1 期
A Phase I, Multicenter, Randomized, Parallel, Double-Blinded Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Dosage Regimens of GW695634G Monotherapy Versus Placebo Over 10 Days in ART-Naive HIV-1 Infected Adults.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 19
- 主要终点
- Safety & tolerability parameters Change from baseline in plasma HIV-1 RNA Change from baseline in CD4+ cell count Plasma GW678248X pharmacokinetic parameters Days 1 & 7
研究概览
简要总结
To investigate safety, tolerability and antiviral activity in Non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced HIV-1 infected patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Safety & tolerability parameters Change from baseline in plasma HIV-1 RNA Change from baseline in CD4+ cell count Plasma GW678248X pharmacokinetic parameters Days 1 & 7
次要结局
- Plasma GW695634X pharmacokinetic parameters on Day 1 and Day 7 Exploratory relationship of pharmacokinetic parameters to changes in virology, immunology and/or safety assessments
研究者
研究点 (19)
Loading locations...
相似试验
已完成
早期 1 期
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIVHIV I InfectionCardiovascular Risk FactorLipid Metabolism DisordersNCT04820933University of Texas Southwestern Medical Center26
已完成
1 期
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and ChildrenHIV InfectionsNCT01504841National Institute of Allergy and Infectious Diseases (NIAID)26
已完成
4 期
NRTI-Sparing Pilot StudyHIVMitochondrial ToxicityNCT00143689University of British Columbia13
已完成
不适用
RETRIeVE: ReversE TranscRiptase Inhibitor hiV PracticeHIV PositiveNCT01154556Holdsworth House Medical Practice2,044
已完成
1 期
Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected SubjectsHepatitis C Virus Infection, Response to Therapy ofNCT01473056Akros Pharma Inc.29